Home glucometer monitoring markedly improves diagnosis of post renal transplant diabetes mellitus in renal transplant recipients

Transplantation

Volumn 80, Issue 6, 2005, Pages 775-781

  Shah, Amish ^a   Kendall, Gwen ^a   Demme, Richard A ^a   Taylor, Jeremy ^a   Bozorgzadeh, Adel ^a   Orloff, Mark ^a   Jain, Ashok ^a   Abt, Peter ^a   Zand, Martin S ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; FEMALE; GLUCOSE BLOOD LEVEL; HOME MONITORING; HUMAN; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RACE; RECIPIENT; SCREENING;

ADULT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS; FEMALE; GLUCOSE INTOLERANCE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS;

EID: 26644438094     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000173769.09518.F1     Document Type: Article

References (42)

1. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3(2): 178.
2. Hathaway DK, Tolley EA, Blakely ML, et al. Development of an index to predict posttransplant diabetes mellitus. Clin Transplant 1993; 7(4): 330.
3. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64(3): 436.
4. Maes BD, Kuypers D, Messiaen T, et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001; 72(10): 1655.
5. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77(2): 252.
6. Hjelmesaeth J, Jenssen T, Hagen M, et al. Determinants of insulin secretion after renal transplantation. Metabolism 2003; 52(5): 573.
7. Parikh CR, Klem P, Wong C, et al. Obesity as an independent predictor of posttransplant diabetes mellitus. Transplant Proc 2003; 35(8): 2922.
8. Hricik DE, Anton HA, Knauss TC, et al. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Transplantation 2002; 74(2): 189.
9. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998; 26(1): 30.
10. Nam JH, Mun JI, Kim SI, et al. Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001; 71(10): 1417.
11. Hjelmesaeth J, Hagen M, Hartmann A, et al. The impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation. Clin Transplant 2002; 16(6): 389.
12. Hagen M, Hjelmesaeth J, Jenssen T, et al. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. Nephrol Dial Transplant 2003; 18(10): 2154.
13. Cosio FG, Pesavento TE, Kim S, et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62(4): 1440.
14. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999; 67(3): 411.
15. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63(7): 977.
16. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69(5): 834.
17. First MR, Gerber DA, Hariharan S, et al. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation 2002; 73(3): 379.
18. Pascual J, Marcen R, Burgos FJ, et al. A low incidence of new-onset insulin-dependent diabetes mellitus using tacrolimus in kidney recipients in Europe. Transplant Proc 2003; 35(5): 1760.
19. Jordan ML, Shapiro R, Jensen CW, et al. FK 506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc 1991; 23(6): 3078.
20. Gabir MM, Hanson RL, Dabelea D, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000; 23(8): 1108.
21. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64(7): 979.
22. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Transplantation 2003; 75(10 Suppl): SS3.
23. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15(7): 539.
24. Screening for type 2 diabetes. Diabetes Care 2003; 26 Suppl 1: S21.
25. Bonora E, Calcaterra F, Lombardi S, et al. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001; 24(12): 2023.
26. Summary of Revisions for the 2004 Clinical Practice Recommendations. Diabetes Care 2004; 27(Suppl 1): S3.
27. Hjelmesaeth J, Jenssen T, Hartmann A. Diagnosing PTDM. Transplantation 2003; 75(10): 1761.
28. Trovati M, Ponziani MC, Massucco P, et al. Blood glucose pre-prandial baseline decreases from morning to evening in type 2 diabetes: role of fasting blood glucose and influence on post-prandial excursions. Eur J Clin Invest 2002; 32(3): 179.
29. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44(11): 1249.
30. Buchanan TA. Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin Ther 2003; 25 Suppl B: B32.
31. Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM 2003; 96(4): 281.
32. Zilker TR, Rebel C, Kopp KF, et al. Kinetics of biosynthetic human proinsulin in patients with terminal renal insufficiency. Horm Metab Res Suppl 1988; 18: 43.
33. Hjelmesaeth J, Midtvedt K, Jenssen T, Hartmann A. Insulin resistance after renal transplantation: impact of immunosuppressive and antihypertensive therapy. Diabetes Care 2001; 24(12): 2121.
34. Filler G, Neuschulz I, Vollmer I, et al. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 2000; 15(6): 867.
35. Nijpels G. Determinants for the progression from impaired glucose tolerance to non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1998; 28 Suppl 2: 8.
36. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46(1): 3.
37. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. Jama 2001; 285(16): 2109.
38. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2005; 28(suppl_1): S37.
39. Borch-Johnsen K, Colagiuri S, Balkau B, et al. Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 2004; 47(8): 1396.
40. Cosio FG, Pesavento TE, Osei K, et al. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 59(2): 732.
41. Suzuki H, Fukushima M, Usami M, et al. Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. Diabetes Care 2003; 26(4): 1211.
42. Abrahamson MJ. Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. Arch Intern Med 2004; 164(5): 486.